| Dr John D Owen, MD | |
|
2609 Glenn Hendren Drive, Liberty, MO 64068-4205 | |
| (816) 781-7730 | |
| (816) 415-1886 |
| Full Name | Dr John D Owen |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 43 Years |
| Location | 2609 Glenn Hendren Drive, Liberty, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356343024 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MDR5H32 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New Liberty Hospital District | Liberty, MO | Hospital |
| Mosaic Medical Center Albany | Albany, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Liberty Hospital Emergency Medicine Physicians Llc | 0749544153 | 16 |
| Northwest Medical Center Association Inc | 5496641896 | 19 |
News Archive
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
Today, a group of health, environmental, and consumer organizations challenged the Food and Drug Administration's (FDA) practice of not accounting for the cumulative health effect of chemicals in the diet when allowing new chemicals in food.
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.
› Verified 9 days ago
| Entity Name | Northwest Medical Center Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124164322 PECOS PAC ID: 5496641896 Enrollment ID: O20040224000204 |
News Archive
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
Today, a group of health, environmental, and consumer organizations challenged the Food and Drug Administration's (FDA) practice of not accounting for the cumulative health effect of chemicals in the diet when allowing new chemicals in food.
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.
› Verified 9 days ago
| Entity Name | Heartland Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477575405 PECOS PAC ID: 6709772767 Enrollment ID: O20040225001201 |
News Archive
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
Today, a group of health, environmental, and consumer organizations challenged the Food and Drug Administration's (FDA) practice of not accounting for the cumulative health effect of chemicals in the diet when allowing new chemicals in food.
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.
› Verified 9 days ago
| Entity Name | Liberty Hospital Emergency Medicine Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336646736 PECOS PAC ID: 0749544153 Enrollment ID: O20180511001882 |
News Archive
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
Today, a group of health, environmental, and consumer organizations challenged the Food and Drug Administration's (FDA) practice of not accounting for the cumulative health effect of chemicals in the diet when allowing new chemicals in food.
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.
› Verified 9 days ago
| Entity Name | Mosaic Medical Center - Maryville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184189797 PECOS PAC ID: 3678813896 Enrollment ID: O20190405001537 |
News Archive
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
Today, a group of health, environmental, and consumer organizations challenged the Food and Drug Administration's (FDA) practice of not accounting for the cumulative health effect of chemicals in the diet when allowing new chemicals in food.
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John D Owen, MD 2609 Glenn Hendren Drive, Liberty, MO 64068-4205 Ph: (816) 781-7730 | Dr John D Owen, MD 2609 Glenn Hendren Drive, Liberty, MO 64068-4205 Ph: (816) 781-7730 |
News Archive
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
Today, a group of health, environmental, and consumer organizations challenged the Food and Drug Administration's (FDA) practice of not accounting for the cumulative health effect of chemicals in the diet when allowing new chemicals in food.
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.
› Verified 9 days ago
Dr. Mitzi E Mathews, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2609 Glenn Hendren Drive, Liberty, MO 64068 Phone: 816-781-7730 Fax: 816-415-1886 | |
Dr. Jordan Haskins, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2525 Glenn Hendren Dr, Liberty, MO 64068 Phone: 816-781-7200 | |
Adam Lee Harrold, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2609 Glenn Hendren Dr, Liberty, MO 64068 Phone: 816-781-7730 Fax: 816-781-6973 | |
Dr. Steven Christopher Nelson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 140 Westwoods Dr, Liberty, MO 64068 Phone: 816-781-4740 Fax: 816-781-0971 | |
Kyle Schneweis, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2609 Glenn Hendren Dr, Liberty, MO 64068 Phone: 816-781-7730 Fax: 816-781-6973 | |
Sheila Owens, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2609 Glenn Hendren Dr, Liberty, MO 64068 Phone: 816-781-7730 Fax: 816-415-1886 | |
Dr. Amy Elisabeth Parry, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9 Victory Dr, Liberty, MO 64068 Phone: 816-792-1809 Fax: 816-792-1860 |